Study record

MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction

Lu H, Wei M, Zhai Y et al. · J Mol Med (Berl) · 2019

AnimalMOTS-c administeredEvidence tier C

What this study reported

In ovariectomized mice, MOTS-c treatment was associated with less weight gain and insulin resistance, more brown fat activation, and less fat accumulation and inflammatory infiltration in white adipose tissue. MOTS-c activated the AMPK pathway, and an AMPK pathway blocker attenuated its effect on adipocyte lipid metabolism.

Limitations

Females only in a single surgical menopause model; group sizes and administration details not reported in the abstract.

Study record

Annotated fields for this study
Study modelAnimal study (in vivo)
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Speciesmouse
System studiedOvariectomized female C57BL/6 mice as a model of postmenopausal metabolic dysfunction
PopulationNot reported
DesignControlled animal experiment
Sample size as reportedNot reported
Control groupovariectomized mice not given MOTS-c (implied); AMPK pathway blocker
Route (data field only)Not reported
Endpoints measuredbody weight and fat mass; insulin resistance; brown fat activation; white adipose inflammation; serum and liver fatty acids; AMPK activation
Pathways measuredAMPK signalling · Thermogenesis / brown fat · Lipid metabolism · Inflammation · Insulin & glucose handling
Research areasMetabolic · Inflammation & immunity
Evidence tierC — Animal in vivo
Publication typesJournal Article, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Mammalian
Sample size
Not reported
Controls
Appropriate
Outcome validity
Surrogate
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.